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ABSTRACT
Objective Hypertensive disorders affect 3–10% of preg-
nancies. Delayed delivery carries maternal risks, while
early delivery increases fetal risk, so appropriate timing is
important. The aim of this study was to compare immedi-
ate delivery with expectant management for prevention of
adverse maternal and neonatal outcomes in women with
hypertensive disease in pregnancy.
Methods CENTRAL, PubMed, MEDLINE and Clinical
Trials.gov were searched for randomized controlled trials
comparing immediate delivery to expectant management
in women presenting with gestational hypertension or
pre-eclampsia without severe features from 34weeks of
gestation. The primary neonatal outcome was respiratory
distress syndrome (RDS) and the primary maternal
outcome was a composite of HELLP syndrome and
eclampsia. The PRISMA-IPD guideline was followed and
a two-stage meta-analysis approach was used. Relative
risks (RR) and numbers needed to treat or harm
(NNT/NNH) with 95% CI were calculated to evaluate
the effect of the intervention.
Results Main outcomes were available for 1724 eligible
women. Compared with expectant management, imme-
diate delivery reduced the composite risk of HELLP
syndrome and eclampsia in all women (0.8% vs 2.8%;
RR, 0.33 (95% CI, 0.15–0.73); I2 = 0%; NNT, 51 (95%
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CI, 31.1–139.3)) as well as in the pre-eclampsia subgroup
(1.1% vs 3.5%; RR, 0.39 (95%CI, 0.15–0.98); I2 = 0%).
Immediate delivery increased RDS risk (3.4% vs 1.6%;
RR, 1.94 (95% CI 1.05–3.6); I2 = 24%; NNH, 58 (95%
CI, 31.1–363.1)), but depended upon gestational age.
Immediate delivery in the 35th week of gestation increased
RDS risk (5.1% vs 0.6%; RR, 5.5 (95% CI, 1.0–29.6);
I2 = 0%), but immediate delivery in the 36th week did
not (1.5% vs 0.4%; RR, 3.4 (95% CI, 0.4–30.3); I2 not
applicable).
Conclusion In women with hypertension in pregnancy,
immediate delivery reduces the risk of maternal complica-
tions, whilst the effect on the neonate depends on gesta-
tional age. Specifically, women with a-priori higher risk of
progression to HELLP, such as those already presenting
with pre-eclampsia instead of gestational hypertension,
were shown to benefit from earlier delivery.  2019
The Authors. Ultrasound in Obstetrics & Gynecology
published by John Wiley & Sons Ltd on behalf of the
International Society of Ultrasound in Obstetrics and
Gynecology.
INTRODUCTION
Hypertensive disorders are present in 3–10% of all
pregnancies1–3. They are among the main causes of
maternal and perinatal morbidity and mortality4–7.
 2019 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd SYSTEMATIC REVIEW
on behalf of the International Society of Ultrasound in Obstetrics and Gynecology.
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Worldwide, between 80 and 120womenwith a pregnancy
complicated by hypertension die each day8.
Delivery of the placenta remains the only definitive
treatment for pregnancy hypertensive disorders. However,
early iatrogenic delivery potentially affects perinatal
outcome. Preterm birth is associated with increased
perinatal mortality and additional morbidity in the short
and long term9–14. Although induction of labor was
considered previously to result in higher Cesarean section
rates15–21, recent studies demonstrate lower or equivalent
rates22–25.
On the other hand, prolonging pregnancies complicated
by hypertensive disorders may increase maternal risk26,27.
Managed expectantly, gestational or chronic hypertension
may progress to pre-eclampsia28,29 or to more severe
complications such as eclampsia, placental abruption or
HELLP syndrome.
Management strategies for hypertensive disorders of
pregnancy have been evaluated at various gestational
ages27,29–31. In the HYPITAT-I trial, women with
gestational hypertension or pre-eclampsia without severe
features from 36+ 0weeks of gestation were randomized
to either immediate delivery or expectant management27.
The Deliver or Deliberate trial evaluated immediate
delivery vs expectant management (until the 37th week of
gestation) for women with pre-eclampsia between 34+ 0
and 36+6weeks of gestation30. The same management
strategies and gestational age range were studied in the
HYPITAT-II trial31.
These trials evaluated different outcomes, gestational
ages and hypertensive disorders and used composite
outcome to overcome the rarity of severe outcomes. They
also had different inclusion and exclusion criteria and
intervention protocols. Therefore, general conclusions
regarding optimal timing of delivery, when the benefits
of immediate delivery outweigh the consequences of early
delivery, are difficult to draw.
Combining individual participant data from these trials
has the potential to overcome some of these drawbacks
and provide stronger evidence to guide clinical practice
and future research. With this aim, we performed
an individual participant data meta-analysis (IPDMA)
comparing immediate delivery to expectant monitoring
for the prevention of adverse maternal and neonatal
outcomes in pregnancies from 34weeks of gestation
complicated by a hypertensive disorder.
SUBJECTS AND METHODS
This IPDMA was registered on PROSPERO (CRD420-
17083348) and its protocol was published after
peer-review32. It is reported in accordance with the
PRISMA-IPD statement33.
Search strategy
An electronic search of CENTRAL, PubMed, MEDLINE
and ClinicalTrials.gov was performed for published or
registered randomized controlled trials (RCT) comparing
immediate delivery with expectant management in
women presenting with gestational hypertension or
pre-eclampsia without severe features from 34weeks
of gestation. The following search strategy was used:
(‘hypertensive disorders of pregnancy’ OR ‘pregnancy
induced hypertension’ OR ‘gestational hypertension’ OR
(‘pre-eclampsia’ OR ‘preeclampsia’) OR (‘hypertension’
AND (‘chronic’ OR ‘chronical*’ OR ‘pre-existent’ OR
‘preexistent’)) AND ‘pregnancy’), with the limits ‘human’
and ‘randomized controlled trial’. The search period
was from database inception to 31 December 2017.
Cluster-randomized trials and quasirandom design studies
were not eligible. Authors of eligible trials were asked
whether they were aware of relevant studies that had not
been identified in the search.
Data collection
Authors of eligible studies were approached to participate
in the IPDMA, comment on the protocol draft and pro-
vide data. Supplied data were assessed for missing data,
internal consistency and randomization. Summary statis-
tics of relevant variables were checked against published
results. Investigators were asked for clarification on dis-
crepancies and a final summary was sent for verification.
After resolution, individual study datasets were merged
into the IPDMA dataset. All included trials were approved
by the relevant committees. Details can be found in the
original manuscripts.
Inclusion and exclusion criteria
Women were included with singleton or multiple preg-
nancy presenting from 34weeks of gestation onwards
with gestational hypertension, pre-eclampsia, dete-
riorating pre-existing hypertension or superimposed
pre-eclampsia.
Hypertension was defined as blood pressure (BP)
levels ≥ 140mmHg systolic or ≥ 90mmHg diastolic and
pre-eclampsia as hypertension and proteinuria (300mg
or more total protein in a 24-h urine sample, recurrent
positive protein dipstick test or protein/creatinine ratio
of 30mg/mmol or more). Deteriorating pre-existing
hypertensionwas defined as the need for new or additional
antihypertensive drugs after 34weeks of gestation in
women with pre-existing hypertension. Superimposed
pre-eclampsia was defined as new onset proteinuria in
women with pre-existing hypertension.
Participants were excluded with signs of severe
disease (BP ≥ 160mmHg systolic or ≥ 110mmHg diast-
olic, proteinuria ≥ 5 g/24 h, oliguria, cerebral/visual
disturbances, pulmonary edema/cyanosis, epigastric or
right upper quadrant pain, impaired liver function and
thrombocytopenia), as well as with diabetes mellitus,
gestational diabetes requiring insulin treatment, kidney or
heart disease, HELLP syndrome or HIV. Pregnancies with
suspected or confirmed major structural or chromosomal
abnormality were also excluded.
 2019 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd Ultrasound Obstet Gynecol 2019; 53: 443–453.
on behalf of the International Society of Ultrasound in Obstetrics and Gynecology.
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Risk of bias assessment
Two investigators (H.G. and T.P.B.) independently
evaluated the included trials for risk of bias. This
assessment was based on criteria found in the Cochrane
Handbook for Systematic Reviews of Interventions34.
The criteria were as follows: random sequence generation;
allocation concealment; blinding of participants and
personnel; blinding of outcome assessment; incomplete
outcome data; selective reporting and other bias. Each
was characterized as low, unclear or high for each trial.
Disagreements were resolved by consensus.
Outcome measures
The primary neonatal outcome was respiratory distress
syndrome (RDS) and the primary maternal outcome
was a composite of HELLP syndrome and eclampsia
(hereafter HELLP or eclampsia). Secondary outcomes
were stroke, cardiac arrest, pulmonary edema, renal
failure, liver failure, disseminated intravascular coagu-
lation (DIC), placental abruption/antenatal hemorrhage,
thromboembolic disease, severe postpartum hemorrhage
(> 1000mL), Cesarean section, neonatal intensive care
unit (NICU) admission, small-for-gestational age (SGA;
birth weight < 10th percentile), 5-min Apgar score < 7,
arterial cord pH < 7.05, bronchopulmonary dysplasia,
seizures, intracerebral hemorrhage, intraventricular
hemorrhage Grade III or IV, cerebral infarction, periven-
tricular leukomalacia, hypoxic ischemic encephalopathy,
necrotizing enterocolitis Grade II or higher and
culture-proven sepsis. A composite adverse maternal
outcome was evaluated, consisting of eclampsia, stroke,
cardiac arrest, pulmonary edema, renal failure, liver
failure, HELLP, DIC, placental abruption/antenatal
hemorrhage and/or thromboembolic disease. A com-
posite adverse neonatal outcome was also evaluated,
consisting of RDS, bronchopulmonary dysplasia, seizures,
intracerebral hemorrhage, intraventricular hemorrhage
Grade III or IV, cerebral infarction, periventricular leuko-
malacia, hypoxic ischemic encephalopathy, necrotizing
enterocolitis Grade II or higher and culture-proven sepsis.
Quality of evidence
To assess systematically the quality of the evidence
provided by the included studies, the approach of the
GRADE Working Group was followed35. Scoring points
were attributed according to type of evidence, quality,
consistency, directness and effect size. The final score was
then used to categorize evidence quality as high, moderate,
low or very low.
Data analysis
Outcomes were analyzed on an intention-to-treat basis
using a two-stage IPDMA approach. Aggregate outcomes
were recalculated at the trial level and then standard
meta-analysis techniques were used to evaluate the
overall effect of the intervention (pooled relative risk
(RR) with 95% CI)36–38. Heterogeneity was assessed
using the I2 statistic. Mantel–Haenszel fixed-effect model
was used if statistical heterogeneity was acceptable
(I2 ≤ 30%) and trial-specific interventions were deemed
sufficiently similar. Random-effects models were used
otherwise. Descriptive comparisons were performed to
assess between-study differences.
Predefined subgroup analyses were performed by hyper-
tensive disorder type, gestational age, obstetric history
(previous hypertensive disorder of pregnancy, Cesarean
section, abortion, parity), ethnicity, multiple pregnancy,
maternal age, body mass index, transvaginal sonography
cervical length and Bishop score. Interactions between
the intervention and subgroups were evaluated using the
chi-square test and resulting interaction P-values.
Statistical analyses were performed using IBM SPSS
Statistics 23 software (version 23.0.0; IBM Corporation,
Armonk, NY, USA) and Review Manager (Version 5.3;
Copenhagen: TheNordic Cochrane Centre, The Cochrane
Collaboration, 2014).
RESULTS
Data were collected on five RCTs: HYPITAT-I, DIGITAT,
Deliver or Deliberate, HYPITAT-II and GRIT27,28,30,31,39.
A summary of the search can be found in Figure 1.
The total number of participants in the trials was
2825. Of these, 1778 were eligible for this study.
Information on non-eligible participants as well as a
summary of each of the five included studies can be
found in Table 1. Baseline characteristics of the 1724
women for whom the primary outcomes were available
can be found in Table 2. The HYPITAT-I, HYPITAT-II
and Deliver or Deliberate studies evaluated immediate
delivery vs expectant management for pregnancies
between 34+0 and 41+ 0weeks of gestation complicated
by hypertensive disorders. HYPITAT-II and Deliver or
Deliberate protocols mandated delivery in the expectant
management group by 37weeks.
Chronologically, HYPITAT-I ran parallel with DIG-
ITAT. Women with hypertension as well as sus-
pected intrauterine growth restriction were preferentially
included in the DIGITAT study. The GRIT trial evaluated
the intervention in pregnancies with fetal compromise
between 24 + 0 and 36 +0 weeks of gestation. GRIT col-
lected data on neonatal outcome only and its main respira-
tory outcome was ventilation for 24 h or more, not RDS.
Randomization to immediate delivery before 37weeks
of gestation resulted in preterm delivery in 86.0%
(435/506) of women. In the expectant management group,
this occurred in 61.0% (303/497). In the former group,
median time to delivery after randomization was 2 days
(interquartile range (IQR), 1.0–3.0) vs 7days (IQR,
4.0–12.0) in the latter. To avoid selection bias because of
fetal compromise, GRIT data were not used to calculate
preterm delivery rates and median time to delivery.
 2019 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd Ultrasound Obstet Gynecol 2019; 53: 443–453.
on behalf of the International Society of Ultrasound in Obstetrics and Gynecology.


















































Studies identified through database search
(n = 5170)
Studies identified through other sources
(n = 2)
Studies after duplicates removed
(n = 2728)
Studies screened for eligibility
(n = 2728)
Studies for which IPD were sought
(n = 6)
Studies for which IPD were provided (n = 5)
 Participants for whom data were provided (n = 2825)
 Participants for whom no data were provided (n = 0)
Studies for which IPD were not provided
(n = 1; 78 participants)
Studies for which aggregate data were available
(n = 1; 78 participants)
  IPD main outcomes
Studies included in analysis (n = 4)
 Participants included in analysis (n = 1724)
 Participants excluded (n = 1101)*
 Aggregate data†
Studies included in analysis (n = 1)
 Participants included in analysis (n = 78)
 Participants excluded (n = 0)
Studies for which IPD were not sought (n = 0)
Studies which were ineligible (n = 2722)
Figure 1 Flowchart summarizing search for, and analysis of, individual patient data from randomized controlled trials reporting on
management of near-term women with hypertensive disorder of pregnancy. *1047 excluded due to individual participant data (IPD)
meta-analysis inclusion/exclusion criteria and 54 from GRIT study39 for which main outcomes were not collected. †Placental abruption,
intrauterine growth restriction, neonatal intensive care unit admission and perinatal mortality.
Table 1 Summary of randomized controlled trials on management of near-term women with hypertensive disorder of pregnancy included in
individual patient data meta-analysis








Sixty-nine hospitals in 13
European countries
547 pregnant women with fetal
compromise between 24+ 0 and
36+0weeks, umbilical artery Doppler
waveform recorded and clinical







Six academic and 32
non-academic hospitals
in The Netherlands
756 women with singleton pregnancy
between 36+ 0 and 41+ 0weeks and
who had gestational hypertension or




Eight academic and 44
non-academic hospitals
in The Netherlands
650 women with singleton pregnancy
between 36+ 0 and 41+ 0weeks with







Single center in USA 169 women who met ACOG 2002
criteria45 for pre-eclampsia without
severe features and gestational dating
34+0 to 36+6weeks
Randomized before











703 women with non-severe hypertensive
disorders of pregnancy between 34+0
and 36+6weeks of gestation
None 703
Only first author of each study is given.
 2019 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd Ultrasound Obstet Gynecol 2019; 53: 443–453.
on behalf of the International Society of Ultrasound in Obstetrics and Gynecology.
Pregnancy hypertension: immediate vs deferred delivery 447
Primary outcomes
Figure 2 presents the primary outcome results by study
and Table 3 presents the pooled results for all outcomes.
Immediate delivery reduced the risk of HELLP or
eclampsia (0.8% vs 2.8%; RR, 0.33 (95%CI, 0.15–0.73);
I2 = 0%; numbers needed to treat (NNT), 51 (95% CI,
31.1–139.3)). Seven of the 861 (0.8%) women in the
immediate delivery group developed HELLP vs 22 of the
863 (2.5%) women in the expectant management group
(RR, 0.36 (95%CI, 0.16–0.80); I2 = 0%;NNT, 58 (95%
CI, 33.9–190.3)). Three expectantly managed women
progressed to eclampsia, one of whom also presented
HELLP. No women in the immediate delivery group
presented eclampsia. There were 29 (3.4%) neonates
with RDS following the 861 immediate deliveries and 14







(in median or %) P
Maternal age (years) 29.0 (25.0–33.0) 29.0 (26.0–33.0) 0.0 0.082
GA at randomization (weeks) 36.0 (35.0–38.0) 36.0 (35.0–38.0) 0.0 0.655
BMI at booking (kg/m2)* 25.8 (22.8–30.5) 25.7 (22.8–29.8) 0.1 0.709
Cervical length (mm)† 32.0 (24.0–40.0) 31.0 (23.0–38.8) 1.0 0.344
Bishop score at randomization‡ 3.0 (2.0–4.0) 3.0 (2.0–4.0) 0.0 0.167
Study 0.186
HYPITAT-I27 377 (43.8) 379 (43.9) –0.1
DIGITAT28 46 (5.3) 64 (7.4) –2.1
Deliver or Deliberate30 86 (10.0) 69 (8.0) 2.0
HYPITAT-II31 352 (40.9) 351 (40.7) 0.2
Hypertensive disease 0.763
Gestational hypertension 355 (41.2) 365 (42.3) –1.1
Pre-eclampsia 392 (45.5) 378 (43.8) 1.7
Chronic hypertension 114 (13.2) 120 (13.9) –0.7
Nulliparous 593 (68.9) 581 (67.3) 1.6 0.502
Caucasian§ 671 (81.2) 665 (80.9) 0.3 0.900
Multiple pregnancy 18 (2.1) 26 (3.0) –0.9 0.285
Data presented as median (interquartile range) or n (%). P-values calculated using Mann–Whitney U-test or chi-square test. Data available
in delivery and expectant management groups, respectively, in: *694 and 718 cases; †721 and 723 cases; ‡700 and 695 cases; §826 and 822































Overall effect Z = 2.74
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Figure 2 Forest plot showing relative risk of HELLP syndrome and/or eclampsia (a) and neonatal respiratory distress syndrome (b) in
women presenting with gestational hypertension or pre-eclampsia without severe features from 34weeks of gestation who underwent
immediate delivery vs those managed expectantly. Mantel–Haenszel fixed-effect model used. NNT/NNH, numbers needed to treat/harm;
EM, expectant management.
 2019 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd Ultrasound Obstet Gynecol 2019; 53: 443–453.
on behalf of the International Society of Ultrasound in Obstetrics and Gynecology.
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(1.6%) in the 863 pregnancies managed expectantly (RR,
1.94 (95% CI, 1.05–3.59); I2 = 24%; numbers needed to
harm, 58 (95% CI, 31.1–363.1)).
Secondary outcomes
Table 3 presents the pooled secondary outcome results.
Severe postpartum hemorrhage occurred in 8.0% of
women after immediate delivery and in 10.4% of women
in the expectant management group (RR, 0.77 (95%
CI, 0.57–1.04); I2 = 2%). The Deliver or Deliberate
and HYPITAT-II studies tracked but did not (plan to)
report on this outcome. Consequently, rates may have
been underestimated in the former, as only three (1.9%)
occurrences were recorded in 155 pregnancies. In the
latter, severe postpartum hemorrhage occurred fewer
times after immediate delivery vs expectant management
(8.5% vs 13.7%; RR, 0.62 (95% CI, 0.40–0.96)).
Table 3 Pooled risk of maternal and neonatal outcomes in women presenting with gestational hypertension or pre-eclampsia without severe




Outcome Events Total Events Total
RR








7 861 24 863 0.33 (0.15–0.73) 27, 28, 30, 31 0 FE 0 High
HELLP syndrome 7 861 22 863 0.36 (0.16–0.80) 27, 28, 30, 31 0 FE 0 High
Eclampsia 0 861 3 863 0.23 (0.03–2.04) 27, 28, 30, 31 0 FE 0 Moderate
PPH 69 861 90 863 0.77 (0.57–1.04) 27, 28, 30, 31 2 FE 0 High
Cesarean section 233 886 245 892 1.02 (0.83–1.26) 27, 28, 30, 31, 39 52 RE 0 Moderate
Pulmonary edema 0 756 2 776 0.20 (0.01–4.17) 27, 28, 31 N/A FE 0 Moderate
Placental abruption 0 756 2 776 0.20 (0.01–4.14) 27, 28, 31 N/A FE 0 Moderate
Placental abruption† 3 794 5 814 0.72 (0.18–2.83) 27, 28, 29, 31 0 FE 0 Moderate
Thromboembolic
disease
2 756 1 776 1.60 (0.25–12.99) 27, 28, 31 0 FE 0 Moderate
CAMO‡ 9 861 28 863 0.35 (0.17–0.72) 27, 28, 30, 31 0 FE 0 Moderate
RDS 29 861 14 863 1.94 (1.05–3.59) 27, 28, 30, 31 24 FE 0 High
NICU admission 53 808 40 798 1.21 (0.69–2.12) 27, 28, 30, 31 40 RE 118/1724 High
NICU admission† 65 846 43 836 1.42 (0.78–2.59) 27, 28, 29, 30, 31 51 RE 118/1800 High
SGA 122 815 146 798 0.84 (0.63–1.13) 27, 30, 31 32 RE 1/1614 High
SGA† 128 853 150 836 0.87 (0.66–1.15) 27, 29, 30, 31 23 FE 1/1690 High
5-min Apgar <7 29 886 20 891 1.43 (0.83–2.48) 27, 28, 30, 31, 39 0 FE 1/1778 High
Seizures 5 728 2 727 2.49 (0.48–12.82) 27, 31 0 FE 0 Moderate
IVH Grade III or IV 3 364 0 363 4.23 (0.49–36.72) 31, 39 0 FE 0 Moderate
NEC ≥ Grade II 4 377 0 376 5.31 (0.64–43.79) 31, 39 0 FE 0 Moderate
Arterial cord
pH<7.05
20 790 28 774 0.70 (0.40–1.24) 27, 28, 30, 31 5 FE 160/1724 High
PVL 4 303 2 284 1.89 (0.34–10.38) 31 N/A FE 0 Moderate
Culture-proven
sepsis
5 775 1 794 2.79 (0.65–11.88) 27, 28, 31 15 FE 0 Moderate
Perinatal mortality 1 886 1 892 1.16 (0.08–17.60) 27, 28, 30, 31, 39 N/A FE 0 Moderate
Perinatal mortality† 3 924 2 930 1.60 (0.27–9.34) 27, 28, 29, 30, 31, 39 0 FE 0 Moderate
CANO§ 47 886 20 892 2.30 (1.38–3.82) 27, 28, 30, 31, 39 11 FE 0 Moderate
BPD 0 886 0 892 — 27, 28, 30, 31, 39 — — — N/A
ICH 0 886 0 892 — 27, 28, 30, 31, 39 — — — N/A
Cerebral infarction 0 886 0 892 — 27, 28, 30, 31, 39 — — — N/A
Hypoxic ischemic
encephalopathy
0 886 0 892 — 27, 28, 30, 31, 39 — — — N/A
Stroke 0 861 0 863 — 27, 28, 30, 31 — — — N/A
Cardiac arrest 0 861 0 863 — 27, 28, 30, 31 — — — N/A
DIC 0 861 0 863 — 27, 28, 30, 31 — — — N/A
Renal failure 0 861 0 863 — 27, 28, 30, 31 — — — N/A
Liver failure 0 861 0 863 — 27, 28, 30, 31 — — — N/A
Data given as n unless otherwise stated. Only first author of each study is given. *References (Refs): HYPITAT-I, Koopmans (2009)27;
DIGITAT, Boers (2010)28; Hamed (2014)29; Deliver or Deliberate, Owens (2014)30; HYPITAT-II, Broekhuijsen (2015)31; GRIT, GRIT
Study Group (2003)39. †Includes aggregate data from Hamed et al.29. ‡Eclampsia, stroke, cardiac arrest, pulmonary edema, renal failure,
liver failure, HELLP, disseminated intravascular coagulation, placental abruption/antenatal hemorrhage and/or thromboembolic disease.
§Respiratory distress syndrome, bronchopulmonary dysplasia, seizures, intracerebral hemorrhage, intraventricular hemorrhage Grade III or
IV, cerebral infarction, periventricular leukomalacia, hypoxic ischemic encephalopathy, necrotizing enterocolitis Grade II or higher and
culture-proven sepsis. BPD, bronchopulmonary dysplasia; CAMO, composite adverse maternal outcome; CANO, composite adverse
neonatal outcome; DIC, disseminated intravascular coagulation; FE, fixed-effects; ICH, intracerebral hemorrhage; IVH, intraventricular
hemorrhage; N/A, not applicable; NEC, necrotizing enterocolitis; NICU, neonatal intensive care unit; PPH, postpartum hemorrhage; PVL,
periventricular leukomalacia; RDS, respiratory distress syndrome; RE, random-effects; RR, relative risk; SGA, small-for-gestational age.
 2019 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd Ultrasound Obstet Gynecol 2019; 53: 443–453.
on behalf of the International Society of Ultrasound in Obstetrics and Gynecology.
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Figure 3 Forest plot showing pooled relative risk of HELLP syndrome and/or eclampsia (a) and neonatal respiratory distress syndrome (b) in
women presenting with gestational hypertension or pre-eclampsia without severe features from 34weeks of gestation who underwent
immediate delivery vs those managed expectantly, according to subgroup. Mantel–Haenszel fixed-effect or *random-effects model used.
BMI, body mass index; EM, expectant management; N/A, not applicable.
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Cesarean section rates were 26.3% in the immediate
delivery group vs 27.5% in those managed expec-
tantly (RR, 1.02 (95% CI, 0.83–1.26); I2 = 52%).
The heterogeneity present is likely derived from the
elevated rate of Cesarean section in the GRIT study;
92% and 75% in the immediate delivery and expectant
management groups, respectively. Comparison restricted
to non-elective Cesarean section showed comparable
results (22.0% vs 22.1%; RR, 1.08 (95% CI, 0.8–1.4);
I2 = 56%).
GRIT and DIGITAT data were not used in the analysis
of SGA because of their inclusion criteria. SGA pooled
rates from the other three studies were 15% for immediate
delivery and 18.3% for expectant management (RR, 0.84
(95% CI, 0.63–1.13); I2 = 32%). The corresponding
rates when GRIT and DIGITAT data were included were
comparable, at 20.3% and 25.1%, respectively (RR, 0.92
(95% CI, 0.79–1.06); I2 =36%). Deliver or Deliberate
and HYPITAT-II did not report on SGA in their respective
papers. In the individual participant data of the former
study, rates were 11.6% vs 8.6% (RR, 1.34 (95% CI,
0.51–3.50)) and in the latter they were 17.6% vs 25.1%
(RR, 0.70 (95% CI, 0.52–0.94)).
The rate of 5-min Apgar score< 7 was 3.3% after
immediate delivery vs 2.2% in pregnancies managed
expectantly (RR, 1.43 (95% CI 0.83–2.48); I2 = 0%),
while NICU admission rates were 6.6% and 5.0%, respec-
tively (RR, 1.21 (95%CI, 0.69–2.12); I2 =40%). Rate of
infants presenting arterial cord pH< 7.05 was 2.5% after
immediate delivery vs 3.6% in the expectant management
group (RR, 0.70 (95% CI, 0.40–1.24); I2 =5%).
Seizures occurred in five infants in the immediate deliv-
ery group and in two in the expectant management
group (0.7% vs 0.3%; RR, 2.49 (95% CI, 0.48–12.82)).
Culture-proven sepsis rates were 0.6% and 0.1%, respec-
tively (RR, 2.8 (95% CI, 0.65–11.88)). Three neonates in
the immediate delivery group presented intraventricular
hemorrhage Grade III or IV and four presented necro-
tizing enterocolitis; none in the expectant management
group presented these outcomes. There were four cases
of periventricular leukomalacia in the immediate delivery
group and two in the expectant management group. There
were no cases of bronchopulmonary dysplasia, intracere-
bral hemorrhage, cerebral infarction or hypoxic ischemic
encephalopathy.
There were two perinatal deaths in the included tri-
als, both from GRIT, one in each group. Inclusion of
aggregate data from Hamed et al.29 on placental abrup-
tion, intrauterine growth restriction, NICU admission,
and perinatal mortality did not change these results sig-
nificantly (Table 3).
Subgroup analyses
Figure 3 shows the results of the subgroup analyses of the
primary maternal and neonatal outcomes. There was no
evidence that the intervention effect was different for any
of the subgroups.
The subgroups of women presenting with
pre-eclampsia, those at or below the median age of
29 years, those who were nulliparous and those with
cervical length greater than the median of 31mm were
at increased risk of HELLP or eclampsia when managed
expectantly.
Infants born after randomization to immediate delivery
at 35weeks of gestation were at higher risk of RDS (5.1%
vs 0.6%; RR, 5.5 (95%CI, 1.0–29.6); I2 = 0%). Of those
randomized to expectant management at 35weeks, 18 of
34 (52.9%) were born at term if the mother presented
with gestational hypertension at randomization. The rate
was similar for women with pre-eclampsia, as 53 of
100 reached term. For those randomized with gestational
hypertension at 34weeks and those randomized with
gestational hypertension at 36weeks, 68.8% (11/16) and
88.3% (68/77), respectively, reached term. In the case of
pre-eclampsia, the respective rates were 17.1% (14/82)
and 84.1% (111/132).
Median time to delivery after randomization to
expectant management at 34weeks of gestation was
16 (IQR, 12.8–19.0) days in cases of gestational
hypertension and 9.5 (IQR, 5.0–16.0) days in cases
of pre-eclampsia. The equivalent medians for 35weeks
were 9.5 (IQR, 5.5–13.0) days and 10 (IQR, 6.0–12.0)
days, respectively, and for 36weeks they were 7 (IQR,
4.0–13.5) days and 5 (IQR, 4.0–8.0) days, respectively.
Pregnancies selected because of fetal compromise were not
included in the subgroup analysis of term birth rates and
median days to delivery for those randomized preterm.
Risk of bias and quality of evidence
The results of our risk of bias evaluation of the studies
based on Cochrane guidelines can be found in Table 4.
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GRADE assessment of quality of evidence and further
data for each outcome are available in Table 3.
DISCUSSION
Primary findings
While immediate delivery decreases the risk of a composite
outcome ofHELLP and eclampsia, it also increases the risk
of RDS, especially if delivery occurs prior to 36weeks
of gestation.
Strengths and limitations
For this IPDMA, we collected and reanalyzed individ-
ual data from five previous RCT on the management of
near-term hypertensive disorders in pregnancy. By har-
monizing inclusion/exclusion criteria and using individual
participant data, we were able to include hypertensive
women from the DIGITAT study.
Unfortunately, we sought but did not receive, data
from Hamed et al.29. Their trial included 76 women
with chronic hypertension, which could have facilitated
our evaluation of this subgroup. Furthermore, as
HYPITAT-II was the only included trial that had data
allowing distinction between pre-eclampsia and super-
imposed pre-eclampsia, we were unable to differentiate
between the two in the pooled results. RDS incidence
is affected by corticosteroid administration prior to
delivery; of the included studies, only HYPITAT-II had
available data on its use. Consequently, no adjustments
were possible to account for this.
Even in our combined dataset, the low incidence of most
severe adverse outcomes remained a difficult challenge.
The results from two currently ongoing trials, i.e. the
PHOENIX trial (ISRCTN01879376) and the WILL trial
(NIHR-HTA - 16/167/123) will have to be awaited to
re-evaluate risks of severe outcomes.
Clinical meaning of findings
The American College of Obstetricians and Gynecol-
ogists (ACOG) currently suggests delivery at 37weeks
of gestation in the presence of gestational hypertension
or pre-eclampsia40. On the other hand, in the UK,
The National Institute for Health and Care Excellence
(NICE) guidelines recommend this only for women with
pre-eclampsia. For women with gestational hypertension,
timing of delivery is left to mutual agreement between
patient and obstetrician41. Our evaluation of pooled data
may contribute to further sophistication of this advice.
Women with gestational hypertension more often devel-
oped HELLP syndrome after expectant management as
compared to immediate delivery. Since the Deliver or
Deliberate andHYPITAT-II trials allowed expectant man-
agement only until 37weeks of gestation, occurrence of
progression to HELLP or eclampsia was precluded. If
allowed to continue beyond this gestational age, these
pregnancies would likely have contributed to an even
larger difference in our primary maternal outcome. There-
fore, our findings strengthen the evidence base for the
ACOG recommendation.
A recently published Cochrane review pooled aggregate
results from the two HYPITAT studies and concluded
that immediate delivery is associated with less composite
maternal morbidity and mortality for women with
a hypertensive disorder after 34weeks’ gestation42.
However, the review authors pooled different composite
outcomes, highlighting the relevance of this IPDMA.
They also found that immediate delivery lowers HELLP
risk, a result that is in accordance with our IPDMA. On
the other hand, they found more NICU admissions after
immediate delivery, which we could not confirm. From
34weeks of gestation to term, current guidelines concur
that management should be expectant as long as no
severe features are present. Our results favor maintaining
this recommendation.
Subgroup analyses
We found no evidence of statistically significant interac-
tion effects present in particular subgroups. This implies
that the relative effects of the intervention do not appear
to differ between subgroups. However, there were sub-
groups with increased risks of RDS or progression
to HELLP or eclampsia.
Women with a-priori higher risk of progression
to HELLP, such as those already presenting with
pre-eclampsia instead of with gestational hyperten-
sion, were shown to benefit from earlier delivery. For
gestational and chronic hypertension, we were not
able to demonstrate a statistically significant differ-
ence in HELLP syndrome and/or eclampsia between the
management groups. Even in our substantial dataset,
conclusions remain difficult to draw for hyperten-
sive disorders other than pre-eclampsia due to their
low prevalence.
The higher rates of the composite outcome of HELLP
syndrome and/or eclampsia found in nulliparous women
and in those with high cervical lengths managed
expectantly are biologically plausible, as both risk factors
contribute to a longer peripartum period and therefore
more opportunity for deterioration.
Immediate delivery at 35weeks was the only gestational
age subgroup with a significantly higher risk of RDS. This
is unlikely to be a false-positive finding because of the
higher prior probability of RDS at this gestational age
when compared to 36 and 37weeks. Incidence of RDS
stabilizes at around 0.3% from the 38th week of gestation
onwards43,44. RDS risk was not elevated for those
randomized at 34weeks, which could be a false-negative
finding or because of insufficient power. On the other
hand, expectant management initiated in the 34th week
of gestation, i.e. between 2+1weeks and 3+0 weeks
before term, did not often result in term delivery. This
was particularly apparent in those with pre-eclampsia
randomized to expectant management, as only 17.1%
reached term. Progression to severe disease or fetal
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distress before term triggered preterm iatrogenic delivery
as per protocol, potentially raising RDS rates to resemble
those in the immediate delivery subgroup. Similar
considerations are valid for the subgroup randomized
at 36weeks with two caveats: (1) RDS rates and severity
at this gestational age are lower than at 34weeks and
(2) the period of opportunity to deteriorate was, at
most, 1 week because of protocol-mandated delivery
at 37weeks44.
In addition to women with pre-eclampsia, the
HYPITAT-II trial included womenwith gestational hyper-
tension. This may explain the contrast with results from
Deliver or Deliberate, which did not include gestational
hypertension. The lower RDS occurrence with expectant
management of preterm gestational hypertension in the
former study possibly occurred because more of these
women were able to reach the 37th week of gestation
without clinical deterioration compared to those with
pre-eclampsia.
Secondary outcome analyses
In agreement with previous RCT-based assessments, we
did not find a higher Cesarean section rate when delivery
was immediate23,24. We found no difference in other
secondary maternal and neonatal outcomes. Although
SGA was reduced by delivery in the HYPITAT-II study,
this was not observed in the Deliver or Deliberate study,
and our pooled results were not conclusive. Whether
immediate delivery sufficiently alleviates prolonged fetal
exposure to a hypertensive environment to decrease SGA
merits further investigation.
Conclusion
Our study can inform women and clinicians in decision
making on the timing of delivery. To reduce the risk
of progression to HELLP or eclampsia, we recommend
immediate delivery of pregnancies complicated by gesta-
tional hypertension or pre-eclampsia by 37weeks of ges-
tation. Despite our large database, uncertainty remains
regarding effects on rare, severe outcomes. Moreover,
long-term consequences of the intervention need to be
investigated and more, larger trials are needed.
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